BRAF and melanoma: Additionally, the proportion of 37% of BRAF V600 mutated patients treated with pembrolizumab underscores the relevance of adjuvant immunotherapy in melanoma despite a given alternative of using BRAF/MEK-inhibitors in the adjuvant setting [17].